FGFR1 controls glucose uptake and utilization by activating the AKT/mTOR pathway, which in turn in involved in the induction of GLUT-1 glucose transporter expression; FGFR inhibitors exert their anti-tumor activity also through the inhibition of glucose metabolism through AKT/mTOR inhibition [56]. Here, AKT1 is linked to neoplasm.